LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Alterations in circulating mitochondrial signals at hospital admission for COPD exacerbation.

    Amado, Carlos A / Martín-Audera, Paula / Agüero, Juan / Ferrer-Pargada, Diego / Josa Laorden, Begoña / Boucle, Daymara / Berja, Ana / Lavín, Bernardo A / Guerra, Armando R / Ghadban, Cristina / Muñoz, Pedro / García-Unzueta, Mayte

    Chronic respiratory disease

    2023  Volume 20, Page(s) 14799731231220058

    Abstract: Background: Chronic obstructive pulmonary disease (COPD) exacerbation (ECOPD) alters the natural course of the disease. To date, only C-reactive protein has been used as a biomarker in ECOPD, but it has important limitations. The mitochondria release ... ...

    Abstract Background: Chronic obstructive pulmonary disease (COPD) exacerbation (ECOPD) alters the natural course of the disease. To date, only C-reactive protein has been used as a biomarker in ECOPD, but it has important limitations. The mitochondria release peptides (Humanin (HN), FGF-21, GDF-15, MOTS-c and Romo1) under certain metabolic conditions. Here, we aimed to evaluate the pathophysiologic, diagnostic and prognostic value of measuring serum mitochondrial peptides at hospital admission in patients with ECOPD.
    Methods: A total of 51 consecutive patients admitted to our hospital for ECOPD were included and followed for 1 year; in addition, 160 participants with stable COPD from our out-patient clinic were recruited as controls.
    Results: Serum FGF-21 (
    Conclusions: Most mitochondrial peptides are altered in ECOPD, as compared with stable COPD. MOTS-c and GDF15 levels have a diagnostic accuracy similar to C-RP for ECOPD. HN and MOTS-c independently predict future re-hospitalization.
    MeSH term(s) Humans ; Disease Progression ; Growth Differentiation Factor 15 ; Prospective Studies ; Hospitalization ; Pulmonary Disease, Chronic Obstructive ; Mitochondria ; Hospitals
    Chemical Substances Growth Differentiation Factor 15
    Language English
    Publishing date 2023-12-18
    Publishing country England
    Document type Journal Article
    ZDB-ID 2211488-9
    ISSN 1479-9731 ; 1479-9723
    ISSN (online) 1479-9731
    ISSN 1479-9723
    DOI 10.1177/14799731231220058
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Circulating levels of mitochondrial oxidative stress-related peptides MOTS-c and Romo1 in stable COPD: A cross-sectional study.

    Amado, Carlos A / Martín-Audera, Paula / Agüero, Juan / Lavín, Bernardo A / Guerra, Armando R / Boucle, Daymara / Ferrer-Pargada, Diego / Berja, Ana / Martín, Fernando / Casanova, Ciro / García-Unzueta, Mayte

    Frontiers in medicine

    2023  Volume 10, Page(s) 1100211

    Abstract: Background: MOTS-c and Romo1 are mitochondrial peptides that are modulated by oxidative stress. No previous studies have explored circulating levels of MOTS-c in patients with chronic obstructive pulmonary disease (COPD).: Methods: We enrolled 142 ... ...

    Abstract Background: MOTS-c and Romo1 are mitochondrial peptides that are modulated by oxidative stress. No previous studies have explored circulating levels of MOTS-c in patients with chronic obstructive pulmonary disease (COPD).
    Methods: We enrolled 142 patients with stable COPD and 47 smokers with normal lung function in an observational cross-sectional study. We assessed serum levels of both MOTS-c and Romo1 and associated these findings with clinical characteristics of COPD.
    Results: Compared with smokers with normal lung function, patients with COPD had lower levels of MOTS-c (
    Conclusions: Reduced levels of circulating MOTS-c and increased levels of Romo1 were detected in patients diagnosed with COPD. Low levels of MOTS-c were associated with oxygen desaturation and poorer exercise capacity using 6 min walk test. Romo1 was associated with current smoking and baseline oxygen saturation.
    Trial registration: www.clinicaltrials.gov; No.: NCT04449419; URL: www.clinicaltrials.gov. Date of registration: June 26, 2020.
    Language English
    Publishing date 2023-02-08
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2775999-4
    ISSN 2296-858X
    ISSN 2296-858X
    DOI 10.3389/fmed.2023.1100211
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: A new, three-dimensional approach to the GOLD COPD assessment tool.

    Golpe, Rafael / Figueira-GonÇalves, Juan Marco / Amado, Carlos A / Martín-Audera, Paula / Esteban, Cristóbal / García-Talavera, Ignacio / Dacal-Rivas, David

    Respiratory medicine and research

    2021  Volume 81, Page(s) 100879

    Abstract: Background: The 2-dimensional, 4-quadrant 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) COPD A-D assessment tool (GOLD: Methods: A total of 1303 COPD patients were included in a historical cohort study. The ability of GOLD: ... ...

    Abstract Background: The 2-dimensional, 4-quadrant 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) COPD A-D assessment tool (GOLD
    Methods: A total of 1303 COPD patients were included in a historical cohort study. The ability of GOLD
    Results: Mean follow-up was 45.0 ± 28.0 months. Two hundred and twenty-eight patients (17.5%) died and 337 (25.9%) subjects suffered at least a severe exacerbation that required hospital admission. The area under the receiver-operating characteristics curve for mortality prediction was slightly but significantly higher for GOLD
    Conclusions: The proposed GOLD
    MeSH term(s) Cohort Studies ; Disease Progression ; Humans ; Predictive Value of Tests ; Pulmonary Disease, Chronic Obstructive/diagnosis ; Pulmonary Disease, Chronic Obstructive/epidemiology ; Severity of Illness Index
    Language English
    Publishing date 2021-12-11
    Publishing country France
    Document type Journal Article
    ISSN 2590-0412
    ISSN (online) 2590-0412
    DOI 10.1016/j.resmer.2021.100879
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Associations between serum mitokine levels and outcomes in stable COPD: an observational prospective study.

    Amado, Carlos A / Martín-Audera, Paula / Agüero, Juan / Lavín, Bernardo A / Guerra, Armando R / Muñoz, Pedro / Berja, Ana / Casanova, Ciro / García-Unzueta, Mayte

    Scientific reports

    2022  Volume 12, Issue 1, Page(s) 17315

    Abstract: Mitokines (Humanin (HN), GDF15 and FGF21) are produced as a result of mitochondrial dysfunction and may have major roles in chronic inflammation, malnutrition and exercise capacity in people with COPD. Except for GDF15, studies on this subject are ... ...

    Abstract Mitokines (Humanin (HN), GDF15 and FGF21) are produced as a result of mitochondrial dysfunction and may have major roles in chronic inflammation, malnutrition and exercise capacity in people with COPD. Except for GDF15, studies on this subject are lacking. A total of 165 patients with stable COPD and 49 smokers without COPD were enrolled. We assessed their serum mitokine levels and clinical characteristics at baseline. We recorded moderate and severe exacerbation for the next 12 months. Baseline serum HN (p = 0.037) and GDF-15 (p = 0.013) levels were higher in the COPD group. High HN levels were independently associated with a high risk of exacerbation (HRE) (OR 2.798, 95% CI 1.266-6.187, p = 0.011), malnutrition (OR 6.645, 95% CI 1.859-23.749, p = 0.004), and 6MWD (OR 0.995, 95% CI 0.991-0.999, p = 0.008), and future moderate (HR 1.826, 95% CI 1.181-2.822, p = 0.007) and severe exacerbations (HR 3.445, 95% CI 1.357-8.740, p = 0.009). High GDF15 levels were associated with HRE (OR 3.028, 95% CI 1.134-8.083, p = 0.027), 6MWD (OR 0.995, 95% CI 0.990-0.999, p = 0.017) and predicted desaturation in 6MWT (OR 3.999, 95% CI 1.487-10.757, p = 0.006). High FGF21 levels were associated with HRE (OR 2.144, 95% CI 1.000-4.600, p = 0.05), and predicted future severe exacerbation (HR 4.217, 95% CI 1.459-12.193, p = 0.008). The mitokine levels were higher in patients with COPD than smokers without COPD, and were associated with important clinical outcomes such as exercise capacity and COPD exacerbation. Among the mitokines, HN showed the strongest association with COPD and may serve as a future risk biomarker in this disease.Trial registation NCT04449419.
    MeSH term(s) Biomarkers ; Disease Progression ; Growth Differentiation Factor 15 ; Humans ; Malnutrition ; Prospective Studies ; Pulmonary Disease, Chronic Obstructive
    Chemical Substances Biomarkers ; Growth Differentiation Factor 15
    Language English
    Publishing date 2022-10-15
    Publishing country England
    Document type Journal Article ; Observational Study
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-022-21757-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top